While DNA and protein diagnostics are common, we specialize in mRNA. Positioned between DNA and proteins, mRNA in whole blood provides a real-time picture of tumor activity. Our novel preservative ensures stable and reliable testing.
History of Wren Laboratories
From History to Innovation: Pioneering mRNA Science to Revolutionize Medicine for Patients
The Power of mRNA
Pioneering Liquid Biopsy
The initial efforts of Sir Christopher Wren in the 1600’s to conduct research on the intravenous transfer of blood inspired the founders of Wren Laboratories to revolutionize how blood can further provide answers for patient care through revolutionary mRNA liquid biopsy for cancer diagnostics.
Our Mission at Wren
We deliver innovative machine learning, liquid biopsy-RNA-based in-vitro diagnostics, for the detection of minimal residual disease and prediction of cancer prognosis and response to therapeutics.
2014
Year Wren Laboratories was founded
135
Number of Patents
30
Number of genes analyzed by the PROSTest®
95%
Clinical accuracy for PROSTest® (vs. 48% for PSA)
55
Number of genes analyzed by the NETest®
Precision Oncology Through mRNA Liquid Biopsy
For decades, cancer management relied heavily on imaging, invasive tissue biopsies, and delayed recognition of residual or recurrent disease. Recognizing the need for more sensitive and dynamic molecular monitoring, Wren’s scientific efforts began exploring liquid biopsy technologies in 2004 to detect cancer-associated genetic activity through circulating biomarkers in blood and other non-invasive specimens.
Today, Wren Laboratories focuses on advanced mRNA-based molecular diagnostics and machine learning–enhanced bioinformatics designed to support earlier cancer detection, molecular surveillance, treatment monitoring, and precision oncology applications. By analyzing tumor-associated genetic signatures from blood and saliva, Wren aims to improve detection of minimal residual disease (MRD), recurrence risk assessment, and real-time disease monitoring through minimally invasive testing.
Wren’s growing portfolio includes molecular assays and translational technologies targeting multiple disease areas, including prostate cancer, neuroendocrine tumors, colorectal cancer, pancreatic cancer, lung cancer, melanoma and hematologic malignancies. The company continues to expand its research, clinical collaborations, and technology platforms to advance the future of non-invasive precision diagnostics.
Through a simple blood or saliva sample, Wren is helping transform mRNA liquid biopsy into a practical clinical reality.
